RE: WYNNIE29 Aug 2025 07:55
Quite a lot in that RNS with the ifs and buts, but my takeaway is that short term this is good because again it has dealt with the short term share dump, however it was over subscribed so I still expect selling pressure but that will be because there is an excellent chance of the SP being above 50p, so its definitely good but still i think we need to be aware that its a very similar exercise to whats gone before, but it has removed the market expectation of uncertainity of where the SP might go every 3 months in this much more ordered short term solution.
The deferral is interesting and also helpful and tells the market that more money (at least £13m?) is coming into the company. The choices including a RI does not take us that much further forward at this stage. Prior to this we were told they were looking at partnerships, so really no change other than to formalise what has been a vaguer pathway previously.
This is all good as this is starting at last to put the meat on the bones and although the options are the same as they have ever bee, specific dates implies this is to a large extent already sorted now and the future finance plan is in place.
It does pave the way for any good trial results not to be overshadowed or diluted by immediate financial concerns.
How this will affect the SP, I don't know as its new news, but I am sure we all expect some sort of increase as it has dealt with the money for next 6-18 months. This will hopefully concentrate attention now on the science and as long as it does not disappoint then this may well be the turning point of AVCT.
(If that view is widely accepted then there should be quite the bounce, however the market has a way of seeing things differently, but at the risk of repeating myself, the detail is what I think, the market will appreciate and react accordingly.)